Compare BioNTech SE - ADR (BNTX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Tidewater Inc — how do they compare? BioNTech SE - ADR trades at $90.1 (market cap $22.86B), while Tidewater Inc trades at $72.79 (market cap $3.68B). The key difference: BioNTech SE - ADR is far larger — about 6.2× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | TDW | |
|---|---|---|
Market Cap | $22.86B | $3.68B |
Sector | Health | Utilities |
52-Week High | $119.34 | $91.12 |
52-Week Low | $83.89 | $46.32 |
Enterprise Value | $6.53B | $3.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Tidewater (TDW) trades at $74.35, up 1.34% today, with a bullish technical outlook driven by moving averages and ADX signals. Recent earnings show volatility with Q1 2026 missing estimates at $0.12 versus $0.75 expected, though Q3 2025 beat expectations. The company maintains strong profitability with a 22.16% net margin and robust cash flow from operations of $379.11M in 2025. News highlights include FTAI Infrastructure's acquisition of Tidewater Logistics in June 2026, potentially impacting operations.
The stock presents a mixed outlook; valuation metrics like a P/E of 12.47 suggest potential undervaluation, but earnings misses and a 'Hold' analyst consensus (61.54% hold ratings) indicate caution. Key risks include execution challenges in offshore support services and oil market volatility. Upside hinges on reversing recent earnings underperformance and capitalizing on industry acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
